Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide

Patent metadata

Field	Value
Publication number	US-10759758-B2
Application number	US-201716097067-A
Country	US
Kind code	B2
Filing date	Apr 25, 2017
Priority date	Apr 29, 2016
Publication date	Sep 1, 2020
Grant date	Sep 1, 2020

Abstract

The present invention relates to crystalline forms of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.

First claim

What is claimed is:

1. A crystalline form of the compound of the formula (I)

selected from the group consisting of polymorph A, polymorph B and 1,7-hydrate, or a mixture thereof,
wherein the polymorph A has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.20: 9.2, 9.8 and 19.3;
wherein the polymorph B has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.20: 9.7, 10.1, and 15.4; and
wherein the 1,7-hydrate has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.20: 10.6, 11.8, and 14.5.

2. The crystalline form of the compound of claim 1 , which is polymorph B.

3. The form of the compound of claim 1 , which is polymorph B has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.20: 9.7, 10.1, 15.4, 16.1, and 20.2.

4. The form of the compound of claim 1 , which is polymorph B has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.20: 9.7, 10.1, 15.4, 16.1, 20.2, and 22.3.

5. The form of the compound of claim 1 , which is polymorph B has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.20: 9.7, 10.1, 15.4, 16.1, 20.2, 22.3, and 25.2.

6. A pharmaceutical composition comprising only one of the crystalline forms selected from the group consisting of polymorphic form A, polymorphic form B, and 1,7-hydrate of the compound of formula (I) according to claim 1 ,
wherein the polymorph A has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.2°: 9.2, 9.8 and 19.3;
wherein the polymorph B has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.2°: 9.7, 10.1, and 15.4; and
wherein the 1,7-hydrate has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.2°: 10.6, 11.8, and 14.5.

7. A pharmaceutical composition comprising a crystalline form of the compound of formula (I)

selected from the group consisting of polymorphic form A, polymorphic form B, and 1,7-hydrate, an amorphous form or a mixture thereof and pharmaceutically acceptable excipients,
wherein the polymorph A has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.2°: 9.2, 9.8 and 19.3;
wherein the polymorph B has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.2 °: 9.7, 10.1, and 15.4; and
wherein the 1,7-hydrate has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value±0.20: 10.6, 11.8, and 14.5.

8. The pharmaceutical composition of claim 7 , comprising only polymorphic form B of the compound of formula (I).

9. The pharmaceutical composition of claim 7 , comprising polymorphic form B of the compound of formula (I) in more than 85 percent by weight related to the total amount of all forms of the compound of formula (I) present in the composition.

10. The pharmaceutical composition of claim 9 , comprising polymorphic form B of the compound of formula (I) in more than 90 percent by weight related to the total amount of all forms of the compound of formula (I) present in the composition.

Assignees

• Bayer Pharma AG

Inventors

• Thaler Tobias
• Platzek Johannes
• Guimond Nicolas

Classifications

• C07D213/86 Primary

  Hydrazides; Thio or imino analogues thereof · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P27/00

  Drugs for disorders of the senses · CPC title

• A61K31/4439 Primary

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61K31/44

  Non condensed pyridines; Hydrogenated derivatives thereof · CPC title